{"nctId":"NCT02553317","briefTitle":"Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura","startDateStruct":{"date":"2015-11","type":"ACTUAL"},"conditions":["Acquired Thrombotic Thrombocytopenic Purpura"],"count":145,"armGroups":[{"label":"Caplacizumab","type":"EXPERIMENTAL","interventionNames":["Biological: Caplacizumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"Caplacizumab","otherNames":["ALX-0081"]},{"name":"Placebo","otherNames":["ALX-0081 Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Adult male or female ≥ 18 years of age at the time of signing the informed consent form (ICF).\n2. Clinical diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) (initial or recurrent), which included thrombocytopenia and microscopic evidence of red blood cell fragmentation (e.g., schistocytes).\n3. Required initiation of daily PE treatment and had received 1 PE treatment prior to randomization\n4. Others as defined in the protocol\n\nExclusion Criteria:\n\n1. Platelet count ≥100×10E9/L.\n2. Serum creatinine level \\>200 µmol/L in case platelet count is \\> 30×10E9/L\n3. Known other causes of thrombocytopenia\n4. Congenital TTP (known at the time of study entry).\n5. Pregnancy or breast-feeding.\n6. Subjects who were previously enrolled in a clinical study with caplacizumab and received caplacizumab or for whom the assigned treatment arm is unknown\n7. Others as defined in the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Platelet Count Response","description":"Platelet count response was defined as initial platelet count ≥ 150,000/μL with subsequent stop of daily PE within 5 days. It refers to the first time both conditions, platelet count ≥ 150,000/μL and the stop of daily PE within 5 days, were met.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.69","spread":null},{"groupId":"OG001","value":"2.88","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Subjects With TTP-Related Death, Recurrence of TTP, or a Major Thromboembolic Event During the Study Drug Treatment Period","description":"Number and percentage of subjects with TTP-related death, a recurrence of TTP, or at least one treatment-emergent major thromboembolic event during the study drug treatment period (i.e., first key secondary endpoint).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Subjects With a Recurrence of TTP in the Overall Study Period","description":"Number and percentage of subjects with a recurrence of TTP during the Overall Study Period (i.e., including follow-up \\[FU\\]) (i.e., second key secondary endpoint).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Subjects With Refractory Disease","description":"Number and percentage of subjects with refractory TTP, defined as absence of platelet count doubling after 4 days of standard treatment, and lactate dehydrogenase (LDH) \\> upper limit of normal (ULN) (i.e., third key secondary endpoint).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Normalization of Organ Damage Marker Levels","description":"Time to first normalization of LDH, cardiac troponin I (cTnI) and serum creatinine was defined as: first time of LDH ≤ ULN and cTnI ≤ ULN and serum creatinine ≤ ULN - time of first i.v. loading dose of study drug after randomization + 1 minute. Subjects in either initial treatment group who switched to open-label caplacizumab before having reached the endpoint were censored at time of switch.\n\nOf note, the key secondary endpoints were hierarchically ordered to allow statistical testing for these endpoints at the same nominal significance level of 5% without adjustment, as long as the tests occurred in the pre-defined sequential order, and given that all null hypotheses tested for endpoints with a higher rank (including the primary endpoint) were rejected. No confirmatory testing was done for this fourth key secondary endpoint, as the statistical test was not significant for the proportion of subjects with refractory disease (i.e., the third key secondary endpoint).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.86","spread":null},{"groupId":"OG001","value":"3.36","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Days of Plasma Exchange","description":"The number of days of PE during the overall study drug treatment period, including the number of days of PE during the open-label study drug treatment period. Data were analyzed according to the initial treatment allocation (both before and after switch to open-label caplacizumab).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"0.51"},{"groupId":"OG001","value":"9.4","spread":"0.81"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Total Volume of Plasma Exchange","description":"The total volume of PE during the overall study drug treatment period, including the total volume of PE during the open-label study drug treatment period. Data were analyzed according to the initial treatment allocation (both before and after switch to open-label caplacizumab).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.33","spread":"1.619"},{"groupId":"OG001","value":"35.93","spread":"4.169"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Days in Intensive Care Unit","description":"The number of days in intensive care unit (ICU) during the overall study drug treatment period, including the number of days in ICU during the open-label study drug treatment period. Data were analyzed according to the initial treatment allocation (both before and after switch to open-label caplacizumab).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.40"},{"groupId":"OG001","value":"9.7","spread":"2.12"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Days in Hospital","description":"The number of days in hospital during the overall study drug treatment period, including the number of days in hospital during the open-label study drug treatment period. Data were analyzed according to the initial treatment allocation (both before and after switch to open-label caplacizumab).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"0.70"},{"groupId":"OG001","value":"14.4","spread":"1.22"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":71},"commonTop":["Epistaxis","Headache","Hypokalemia","Nausea","Catheter site hemorrhage"]}}}